GO
Loading...

Novartis AG

More

  • *CEO says Roche committed to Switzerland despite franc rise. While cross-town rival Novartis has said it will review its Swiss cost base, Roche Chief Executive Severin Schwan said his company had no plans to move operations. "I continue to believe that Switzerland and Basel offer a very good framework for our business," Schwan told reporters.

  • Swiss drug maker Novartis posts Q4 profit drop Tuesday, 27 Jan 2015 | 3:36 AM ET

    BERLIN— Swiss pharmaceutical giant Novartis AG says fourth quarter net income dropped 26 percent but the company still posted a healthy 2014 annual profit. The Basel, Switzerland- based company said Tuesday that fourth quarter net income came in at $1.49 billion, down from $2 billion in the same quarter the year before excluding its blood-transfusion...

  • *Core EPS $1.21 vs $1.18 forecast in Reuters poll. ZURICH, Jan 27- Swiss drugmaker Novartis forecast sales and profits to grow at a faster pace this year as recent drug successes and its portfolio overhaul help it weather the impact of generic competition. Novartis unveiled a transformative series of deals last year which will see it focus on a smaller number of...

  • We're looking for bolt-on acquisitions: Novartis CEO  Tuesday, 27 Jan 2015 | 1:45 AM ET

    Joe Jimenez, CEO of Novartis, says the company is looking to carry out merger and acquisition deals in 2015 to compliment its existing businesses.

  • NEW YORK, Jan 26- A new wave of experimental cancer drugs that directly recruit the immune system's powerful T cells are proving to be immensely effective weapons against tumors, potentially transforming the $100 billion global market for drugs that fight the disease. But top oncology researchers are concerned about the two emerging technologies, citing...

  • FDA approves 2nd vaccine against meningitis strain Friday, 23 Jan 2015 | 5:07 PM ET

    WASHINGTON— Federal health regulators have approved a second vaccine to prevent a strain of bacteria that can cause deadly cases of meningitis. The Food and Drug Administration said it cleared Novartis' Bexsero vaccine against a subtype of meningococcal bacteria in people ages 10 to 25. The agency cleared a similar vaccine from Pfizer last October.

  • Shares of Array BioPharma soared Friday after the drug developer said it will buy worldwide rights to a potential cancer treatment in late-stage clinical testing from Swiss pharmaceutical giant Novartis. The Boulder, Colorado, company said the deal is conditional on Novartis closing some acquisitions with British drugmaker GlaxoSmithKline PLC that it...

  • Lori Simons took the bright orange pill at 3 a.m. Eight hours later, doctors sliced into her brain, looking for signs that the drug was working. With special permission from the Food and Drug Administration and multiple drug companies, an Arizona hospital is testing medicines very early in development and never tried on brain tumors before.

  • Lori Simons took the bright orange pill at 3 a.m. Eight hours later, doctors sliced into her brain, looking for signs that the drug was working. With special permission from the Food and Drug Administration and multiple drug companies, an Arizona hospital is testing medicines very early in development and never tried on brain tumors before.

  • DUBLIN/ FRANKFURT, Jan 22- Business leaders in Europe gave a mixed welcome to the European Central Bank's moves to bolster growth and inflation in the euro area on Thursday, with many- especially in Germany- concerned the programme could delay unpopular economic reforms. "This is a step in the right direction and we'll have to watch and see how it plays out," Swiss...

  • We are funding part of ACA: Novartis CEO  Thursday, 22 Jan 2015 | 8:14 AM ET
    Joe Jimenez, CEO of Novartis, at 2015 WEF in Davos, Switzerland.

    Joe Jimenez, Novartis CEO, discusses how the move in the Swiss franc impacted his company, innovative drugs in the pipeline, and pharmaceutical pricing issues.

  • Meet Morningstar's fund managers of the year Wednesday, 21 Jan 2015 | 5:42 PM ET

    Here are the fund managers Morningstar considers the best of the best.

  • Jan 21- The U.S. Food and Drug Administration approved Novartis AG's injectable drug, Cosentyx, to treat adults with a moderate to severe skin disease called plaque psoriasis. Eli Lilly and Co will begin marketing its IL-17 inhibitor ixekizumab in the first half of 2015, while Amgen Inc and AstraZeneca Plc's brodalumab reported positive results from a...

  • FDA approves Novartis's psoriasis drug Wednesday, 21 Jan 2015 | 12:49 PM ET

    Jan 21- The U.S. Food and Drug Administration said it approved Novartis AG's drug to treat adults with moderate to severe plaque psoriasis.

  • WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries Ltd can still benefit from patent protection for top-selling multiple sclerosis drug Copaxone, dealing a blow to generic drugmakers looking to market a cheaper rival product. In a 7-2 vote, the justices sent the case back to the U.S. Court of Appeals for the Federal...

  • Within minutes of the Swiss National Bank's announcement it was ditching a policy to limit the rise of the currency, the franc had rocketed by about a third against the euro and the dollar. That's a clear indication investors have taken fright at the worsening outlook for Switzerland's exporters and economy. According to Morgan Stanley, 85 percent of Swiss...

  • LONDON, Jan 16- GlaxoSmithKline is feeling the heat from the rapid growth in electronic cigarettes, with enthusiasm for the nicotine delivery devices dampening sales of the British drugmaker's patches and gum, its chief executive said. In an interview with Reuters, Andrew Witty also said he and his team had spent "a few days" exploring whether the drugmaker...

  • *Consumer more tenable as standalone business after Novartis deal. Chief Executive Andrew Witty told Reuters the group's large consumer health business would be more viable as a standalone operation following the conclusion of a $20 billion asset swap with Novartis, especially if it bought additional assets. "Post- Novartis, particularly if we did more...

  • *Bank of America, Citi fall after results. *Swiss National Bank scraps three-year-old euro cap on franc. "We're probably going to see slowing in the global economy, and it will be very difficult to sail through a global recession without getting touched," said Scott Colyer, chief executive officer of Advisors Asset Management in Monument, Colorado.

  • *Bank of America, Citi down after results. *Swiss National Bank moves to scrap 3- year euro cap on the franc. Swiss stocks traded in the United States moved higher, Credit Suisse, up 0.7 percent at $22.98 and Novartis, up 1.9 percent to $98.61, as a strengthening Swiss franc made U.S.-dollar denominated stocks cheaper.